Somapacitan Reference

Plain English

What it is

Somapacitan is a prescription medicine sold under the brand name Sogroya. It is a long-acting, lab-made copy of human growth hormone that is given as a shot under the skin once a week.

What people use it for

Doctors prescribe it to replace growth hormone in adults whose bodies do not make enough, and to help certain children who are not growing as expected. In early 2026 the FDA expanded its approval to cover more childhood growth conditions, including idiopathic short stature, being born small with no catch-up growth, and growth problems linked to Noonan syndrome.

What the science shows

This is an FDA-approved drug backed by human clinical trials, so its benefits and risks for its approved uses are well studied. Reported side effects in adults include things like back pain, joint pain, indigestion, swelling, and higher blood pressure, while children commonly report cough, headache, fever, and reactions where the shot is given.

The catch

This is a real growth hormone medicine, not a supplement, and it is legal only with a prescription for an approved condition. Federal law makes it a crime to give out human growth hormone for uses the FDA has not approved, such as anti-aging or building muscle. Growth hormone is also banned in sport at all times under anti-doping rules, so tested athletes face penalties.

Reference summary

Somapacitan is a label-verified long-acting somatropin analog dosed once weekly across adult and pediatric growth-disorder indications. pepSmart surfaces label-reference content only.

Regulatory and posture

Categories

GH Release, Hormonal

Aliases

Sogroya, Long-acting somatropin analog

Evidence posture

human - Recombinant human growth hormone analog. WADA-prohibited at all times under category S2. Prescription-only; possession or distribution outside an FDA-approved indication is restricted by the Anabolic Steroid Control Act.

Regulatory status

FDA-approved prescription medication (Sogroya). Indicated for adults with growth hormone deficiency (2020) and for pediatric patients 2.5 years and older with GHD (2023); on February 27, 2026 the FDA added three pediatric indications: short stature born small for gestational age without catch-up growth, growth failure associated with Noonan syndrome, and idiopathic short stature. WADA-prohibited under category S2 at all times. Distribution and possession outside an approved indication is restricted under the United States Anabolic Steroid Control Act.

Content review status

label verified

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.
• Protocol builder overview - Public overview of the Pro protocol builder.